Aptose Biosciences Inc.
Home
About
Overview
Management Team
Board of Directors
Scientific Advisory Board
Product Pipeline
Overview
Tuspetinib for AML
Luxeptinib for B-cell Tumors
Luxeptinib for Myeloid Tumors
Posters & Presentations
Clinical Trials
Overview
Luxeptinib for CLL & NHL
Luxeptinib for AML
Tuspetinib for AML
Expanded Access
News
Press Releases
Presentations
Events
Investors
Overview
News & Events
Company Info
Financial Info
Stock Data
SEC Filings
SEDAR
Governance
Join Us
Values & Culture
Perks & Benefits
Explore Careers
Contact
Posters & Presentations
Product Pipeline
Product Pipeline
Overview
Tuspetinib for AML
Luxeptinib for B-cell Tumors
Luxeptinib for Myeloid Tumors
Posters & Presentations
All
Poster
Presentation
November 7, 2024
Presentation
Aptose Corporate Presentation November 2024
Aptose Corporate Presentation November 2024:
View Presentation
July 26, 2024
Presentation
Aptose Corporate Presentation July 2024
Aptose Corporate Presentation July 2024:
View Presentation
May 3, 2024
Presentation
Aptose Corporate Presentation May 2024
Aptose Corporate Presentation May 2024:
View Presentation
December 26, 2023
Presentation
Aptose Corporate Presentation December 2023
Aptose Corporate Presentation December 2023:
View Presentation
December 9, 2023
Presentation
Tuspetinib Oral Myeloid Kinase Inhibitor Safety and Efficacy As Monotherapy and Combined with Venetoclax in Phase 1/2 Trial of Patients with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML)
Tuspetinib Oral Myeloid Kinase Inhibitor Safety and Efficacy As Monotherapy and Combined with Venetoclax in Phase 1/2 Trial of Patients with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML):
View Presentation
October 30, 2023
Presentation
Tuspetinib Clinical Update and KOL Data Review
Tuspetinib Clinical Update and KOL Data Review:
View Presentation
September 11, 2023
Presentation
Aptose Corporate Presentation September 2023
Aptose Corporate Presentation September 2023:
View Presentation
June 10, 2023
Presentation
Aptose Interim Clinical Update
Aptose Interim Clinical Update:
View Presentation
April 13, 2023
Presentation
Aptose Corporate Presentation April 2023
Aptose Corporate Presentation April 2023:
View Presentation
1
2
3
Next